Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.
- Associate Professor, Epidemiology, Boston University School of Public Health
- New York University School of Medicine, MD
- Harvard School of Public Health, MPH
- Yale University, BA
- SPH EP762
- Published on 10/16/2017
Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR, Marks SM, Linas BP. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. JAMA Intern Med. 2017 Oct 16. PMID: 29049814.
- Published on 10/15/2017
Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA. Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2017 10 15; 65(8):1266-1271. PMID: 28605504.
- Published on 10/4/2017
Cohen GH, Tamrakar S, Lowe S, Sampson L, Ettman C, Linas B, Ruggiero K, Galea S. Comparison of Simulated Treatment and Cost-effectiveness of a Stepped Care Case-Finding Intervention vs Usual Care for Posttraumatic Stress Disorder After a Natural Disaster. JAMA Psychiatry. 2017 Oct 04. PMID: 28979968.
- Published on 9/9/2017
Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clin Infect Dis. 2017 Sep 09. PMID: 29020317.
- Published on 7/3/2017
Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2017 Jul 03. PMID: 28733097.
- Published on 6/1/2017
Barocas JA, Beiser M, León C, Gaeta JM, O'Connell JJ, Linas BP. Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. JAMA Intern Med. 2017 Jun 01; 177(6):880-882. PMID: 28395004.
- Published on 12/27/2016
Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis. 2017; 4(1):ofw266. PMID: 28480259.
- Published on 11/3/2016
Barocas JA, Linas BP. Editorial Commentary: Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. Clin Infect Dis. 2017 Jan 01; 64(1):100-101. PMID: 27815292.
- Published on 7/1/2016
Linas BP. Understanding Cost and Value in Hepatitis C Therapy. Top Antivir Med. 2016 Jul/Aug; 24(2):93-97. PMID: 27841979.
- Published on 6/21/2016
Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Sep 06; 165(5):345-55. PMID: 27322622.
View 28 more publications: View full profile at BUMC